Silverarc Capital Management, LLC Bio Atla, Inc. Transaction History

Silverarc Capital Management, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $2.64 Million - $3.81 Million	346,453 Added 172.86%	546,875 $4.51 Million
Q3 2022 Oct 28, 2022	BUY	$2.94 - $11.87 $589,240 - $2.38 Million	200,422 New	200,422 $1.54 Million

24.8M

140K

4.6K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $47.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.